| Nov 19 |
Merck readies new Keytruda version ahead of major regulatory headwinds
|
| Nov 19 |
Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients
|
| Nov 19 |
Merck raises dividend to $0.81/share
|
| Nov 19 |
Merck Announces First-Quarter 2025 Dividend
|
| Nov 19 |
Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
|
| Nov 19 |
Merck says injectable Keytruda succeeded in late-stage trial
|
| Nov 19 |
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
|
| Nov 19 |
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
|
| Nov 18 |
Jim Cramer Says Merck & Co., Inc. (MRK) Is ‘Just Way Too Hated’
|
| Nov 18 |
Is Merck & Co., Inc. (MRK) the Best Immunotherapy Stock to Buy Now?
|
